Ares

This research focuses on women aged 18 to 65 with symptoms of acute cystitis without risk of complication. It aims to evaluate whether using a shared decision-making tool in pharmacies can help patients better understand the benefits and risks of taking antibiotics and adjust antibiotic use accordingly. The goal is to reduce unnecessary antibiotic prescriptions while still selecting patients who truly need treatment. Participants are divided into two groups. One group follows the standard French delegation protocol for acute cystitis management by pharmacists, which recommends systematic antibiotic therapy. The other group uses the same protocol supplemented with a shared decision-making tool to decide if antibiotics should be given based on patient preferences after being informed. This study compares antibiotic dispensing between these groups. After diagnosis and consent, patients receive care according to their group assignment. Researchers collect data on antibiotic prescriptions and patient demographics. Participants are followed up by phone 14 days later to assess antibiotic use, symptom impact using the Activity Impairment Assessment scale, satisfaction, decision confidence via the OConnor scale, and any medical visits. Antibiotic dispensing is tracked through national pharmacy records. The study runs from May 2026 to November 2026.

This research aims to describe how patients aged 18 years or older with moderate to severe atopic dermatitis AD are managed with systemic therapy. It focuses on patients eligible for or currently receiving systemic treatments, following their care under real-world conditions. The study involves French dermatologists experienced in AD management, whether practicing in hospitals or private offices. Treatment decisions are made independently by the physicians and not influenced by the study enrollment. Participants will receive systemic treatments for AD prescribed by their doctors as part of routine care, with no investigational drugs involved. Information will be collected during regular visits according to usual clinical practice. The study will follow patients for one year, tracking their treatments and management without altering standard care. During the year, patients will be assessed at baseline, 6 months, and 12 months. Researchers will collect data on previous and current treatments, treatment adherence, changes in disease severity, itch, sleep disturbance, skin pain, quality of life, psychological health, work absences, and hospitalizations related to AD. This comprehensive follow-up aims to better understand how systemic therapies are used and their impact on patients in everyday clinical settings.